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When we make decisions in both research and clinical care the
objective is to make a difference. That’s why we’re here, right? This
question and reflex answer is routinely in my head and now it’s been
amplified by the COVID-19 pandemic.
Understanding the needs and priorities of my hospital here in the
UK offers a stark contrast with the limited medical resources and cop-
ing abilities of The Gambia. And I know that across Africa and in other
low-income countries, the situation will be much the same.
As a specialist in paediatric infectious diseases, there are options
for how best I can contribute to the national effort to combat this
virus. I could support the NHS as a clinician; use my academic skills
to advance research on vaccines, advocating for their use: or try to
mitigate the collateral damage that is going to arise from this pan-
demic by highlighting the need for vaccines and child health services.
Yet back in The Gambia, options are a rare luxury. My colleagues
struggle to get potentially life-saving tests and clinical equipment
delivered. Critical research is virtually on hold, including my own
advanced vaccine trials. So, should I be writing different grants, should
I jump on the bandwagon of the only-funding-show-in-town right
now to keep our teams going? Such thoughts more or less sum up my
dual life as clinician-scientist working in both the UK and sub-Saharan
Africa. This is not a source of complaint, because there are rich experi-
ences and worthy dilemmas that emanate from combining scientific
research in vaccines and immunity with a clinical perspective.
Translation of laboratory science to policy and practice is a long
road, but in my field of vaccine research it is a particularly rewarding
one. To start from assessing immune responses elicited by a novel
vaccine in a small group of volunteers, and to reach the productive
time when this vaccine is licensed and introduced into the WHO-rec-
ommended Expanded Program of Immunization (EPI), knowing the
lives of thousands of children who might otherwise suffer from men-
ingitis or pneumonia will instead be saved  well, that answers myE-mail addresses: beate.kampmann@lshtm.ac.uk, bkampmann@mrc.gm,
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effort all worthwhile [1].
To test novel diagnostics for children with tuberculosis and figure
out what works for children and what doesn’t is necessary [2]. But as
we still don’t have a perfect answer, we plough on. To study the
development of the neonatal immune system in unprecedented
depth with systems biology tools and to discover all of the changes in
just the first week of life has been fascinating [3]  though to be able
to apply this new knowledge to inform the next generation of vac-
cines remains an ambition for now. To prevent infections in babies
because a vaccine can be given to their mothers in pregnancy, has
been utterly rewarding, and yet I know there is so much scope for
more to be done [4]- both in discovery and implementation.
All the positives I describe here cannot be achieved without
teams, without a collective effort. To work together with my highly
valued global community of students, postdocs and colleagues has
been one of the best parts of my career.
This job - if that is the correct word - is never done [5], but it will
always get me out of bed with full enthusiasm, energy-sapping pan-
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